UK Pricing Deal To Address Barriers to New Drug Uptake

Under the UK’s newly published voluntary pricing and access scheme, stakeholders will be more easily able to track a new product’s journey from the development pipeline to licensing and on to commissioning by the National Health Service. A close eye will also be kept on any access problems caused by variations in the implementation of HTA guidance.